RiverVest
RiverVest Venture Partners is a St. Louis-based venture capital firm founded in 2000 that builds and invests in early-stage biopharma and medical device companies, deploying capital from institutional LPs across multiple funds and generating returns through management fees and carried interest.
- Company typePrivate
- Founded2000
- HeadquartersSt Louis, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What RiverVest does
RiverVest Venture Partners is a St. Louis-based venture capital firm founded in September 2000 that builds and backs early-stage life science companies, exclusively focused on biopharma and medical devices. The firm has raised eight vehicles to date: five core funds (Fund I through Fund V, with Fund V at $275M in March 2021), the Archer Seed Fund for very early-stage company formation (launched November 2016), and two 3x5 joint vehicles with Arnerich Massena for later-stage life science investments. Across 25 years the firm has made 61 investments and produced 41 exits, with 30+ commercial products treating patients and 18 companies co-founded by the partnership. Documented outcomes include the Lutonix exit at 8.0x gross, the Lumena/Shire transaction delivering approximately $400M to investors, Allakos's 2018 IPO at a 9x return, Standard Bariatrics and Good Therapeutics acquired in September 2022, and Bluejay Therapeutics acquired by Mirum Pharmaceuticals in January 2026.
The firm invests behind products with known paths to clinical or regulatory approval rather than platform technologies, sourcing deals through a proprietary innovation network of entrepreneurs, KOLs, and academic institutions (including formal partnerships with BioGenerator/BioSTL, Washington University in St. Louis, and BioEnterprise). Its team of approximately 16 operates from offices in St. Louis (headquarters), San Diego (opened April 2016), and Cleveland (opened January 2008). Revenue is generated through the standard VC model of management fees (typically ~2% of committed capital) on funds raised from institutional Limited Partners, plus carried interest (typically ~20%) on profitable exits. The most recent senior promotions in December 2023 (Karen Spilizewski and Isaac Zike to Managing Director, Pascal Krotee to Principal) indicate succession planning within a partnership led by co-founders Jay Schmelter and Thomas Melzer.
RiverVest firmographics
Firmographics- Name
- RiverVest
- Legal name
- RiverVest Venture Partners
- Website
- https://rivervest.com
- Company type
- Private
- Founded year
- 2000
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- RiverVest Venture Partners is a St. Louis-based venture capital firm founded in 2000 that builds and invests in early-stage biopharma and medical device companies, deploying capital from institutional LPs across multiple funds and generating returns through management fees and carried interest.
- Ownership category
- akta.pro rank
RiverVest industry classification
Industry- Product category
- Life Science Venture Capital
- NAICS
- Funds, Trusts, and Other Financial Vehicles (525), Portfolio Management and Investment Advice (523940)
- SIC
- Investment Advice (6282)
- akta.pro primary industry
- Sector-Focused Venture Capital (Vertical Specialists) (FSANAAAD)
- akta.pro secondary industry
- Early-Stage Venture Capital (Series A/B) (FSANAAAB)
Keywords
Where RiverVest is headquartered
LocationHeadquarters
- HQ city
- St Louis
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
RiverVest business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D, Others
Revenue model
- Management Fees: VC firms typically charge management fees on committed capital, typically 2% of assets under management, charged annually to cover operational expenses.
- Carried Interest: The firm earns carried interest (typically 20%) on profits from successful portfolio company exits, representing the primary performance-based revenue stream.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels6 records
RiverVest product offering
Product offeringCore offering
RiverVest Venture Partners is a life science venture capital firm that raises dedicated funds (Funds I through V, the Archer Seed Fund, and the 3x5 Special Opportunity Fund) from institutional investors and invests the committed capital as equity into early-stage biopharmaceutical and medical device companies. The firm earns revenue through management fees on committed capital and carried interest on profitable exits, and provides portfolio companies with board representation, strategic guidance, and access to its scientific and clinical network.
Product overview
RiverVest Venture Partners is a leading life science venture capital firm offering investment vehicles across multiple funds (Fund I through Fund V, Archer Seed Fund, and 3x5 Special Opportunity Fund) that invest in biopharma and medical device companies. The firm has made 61 investments and achieved 41 exits, with 30+ commercial products treating patients. Their portfolio spans therapeutic areas including rare diseases, oncology, neurological disorders, pulmonary diseases, metabolic conditions, and medical devices for cardiovascular and surgical applications. RiverVest provides capital, strategic guidance, and operational support to early-stage life science companies from seed through exit.
Differentiator
Problem solved
Functional benefit
Products and services
- RiverVest Venture Fund I RiverVest's inaugural life science venture capital fund, raised in September 2000, which deployed capital into early-stage biopharma and medical device companies and whose portfolio investments led to 16 commercial products treating patients.
- RiverVest Venture Fund II RiverVest's second life science venture capital fund, raised in August 2006, which became a top-quartile performer; John McKearn, Ph.D., and Niall O'Donnell, Ph.D., joined to develop a successful biopharma strategy.
- RiverVest Venture Fund III RiverVest's third life science venture capital fund, raised in March 2014, continuing the successful biopharma and medical device investment strategy of Fund II.
- RiverVest Venture Fund IV RiverVest's fourth life science venture capital fund, raised in December 2017, which later ranked in the top quartile DPI of 2018 vintage year funds.
- RiverVest Venture Fund V RiverVest's fifth life science venture capital fund, raised in March 2021 with $275 million in LP commitments; backs biopharma and medical device portfolio companies and completed follow-on investments in nine companies in 2025.
- Archer Seed Fund RiverVest's seed-stage fund, launched in November 2016, that invests in a small number of promising very early-stage companies to position them for later venture financing; portfolio includes Wugen and Scout Bio.
- 3x5 Special Opportunity Fund A venture capital fund launched in September 2011 as a joint venture with Portland-based Arnerich Massena, with a concentrated portfolio of later-stage life science investments.
Quantifiable outcome
- 23+ successful exits and 32 products reaching market
- +3 more outcomes
Companies that use RiverVest
Customer profileNamed customers6 records
Segments3 records
Ideal customer profiles2 records
RiverVest technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
RiverVest partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core and minor.
- BioGenerator / BioSTLcoreBioGenerator, the investment arm of nonprofit BioSTL in St. Louis, co-founded Wugen with RiverVest. They provide funding and lab space for startup companies.
- Washington University in St. LouiscoreTechnology licensed from Washington University for Wugen's CAR-T therapy platform. RiverVest co-founded Wugen based on this technology.
- BioEnterpriseminorCleveland-based venture accelerator. Karen Spilizewski split time between RiverVest and BioEnterprise until 2020, working to identify and accelerate emerging medical device companies.
Scale indicators9 records
Recent moves16 records
Expansion highlights6 records
RiverVest competitors and assessment
Company assessmentBroad incumbents
- New Enterprise Associates (NEA): NEA is a large, diversified venture capital firm with a significant dedicated healthcare practice spanning biopharma, medical devices, and digital health. Comparable to RiverVest in life science investing and company-building, but operates at much greater scale across technology, healthcare, and other sectors.
Direct peers
- OrbiMed: OrbiMed is a healthcare-dedicated investment firm managing billions across venture, growth, and public equities in biopharma, medical devices, and diagnostics. Comparable to RiverVest as a sector-specialist VC that invests across stages of life science company development with a similar product-focused thesis.
- Atlas Venture: Atlas Venture is a Boston-based early-stage life science venture capital firm that builds companies from inception around emerging science. Highly comparable to RiverVest in fund size (~$400M-$450M recent funds), company-creation model, and focus on biopharma with operational scientist-investors.
- ARCH Venture Partners: ARCH Venture Partners is a large life science and technology venture capital firm that funds early-stage biotechnology, medical devices, and platform companies. Comparable to RiverVest in its focus on deep-tech life sciences, university spinouts, and founding companies around breakthrough science, though at much larger fund sizes.
- Longitude Capital: Longitude Capital is a healthcare-focused venture capital firm investing in medical devices and biopharmaceutical companies across all stages. Comparable to RiverVest in its dedicated healthcare focus, multi-stage strategy, and emphasis on growth-stage clinical and commercial investments.
- Frazier Life Sciences: Frazier Life Sciences is a dedicated healthcare/life sciences venture capital firm investing across public and private biopharma and medical device companies. Comparable to RiverVest in sector focus, multi-fund structure, and approach of taking concentrated positions in clinical-stage companies.
- Hatteras Venture Partners: Hatteras Venture Partners is a venture capital firm investing in early-stage healthcare and life science companies across biopharma, medical devices, and diagnostics. Highly comparable to RiverVest in stage, sector, fund size, and Southeast/Midwest regional orientation; has even co-invested with RiverVest in deals like Standard Bariatrics.
- Versant Ventures: Versant Ventures is a healthcare-focused venture capital firm investing across biopharma, medical devices, and diagnostics across all stages. Like RiverVest, it is a sector specialist with multiple funds, a history of founding companies, and an emphasis on building teams around validated science.
- 5AM Ventures: 5AM Ventures is an early-stage life science venture capital firm that invests in platform and product-focused biopharma companies. Like RiverVest, it operates with a science-driven, company-building approach and runs multiple funds targeting startup and clinical-stage opportunities.
- Sanderling Ventures: Sanderling Ventures is one of the oldest dedicated life science venture capital firms, investing across all stages of medical devices and biopharmaceuticals. Highly comparable to RiverVest in its longevity (founded 1979), multi-fund structure, and 100% sector focus on medical devices and biopharma company building.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
RiverVest social profiles
Digital presenceRiverVest financial estimates
Financial estimateRevenue estimate
Valuation estimate
RiverVest leadership team
Management profileNumber of profiles
Profiles16 records
RiverVest funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
RiverVest M&A and investment
M&A and investmentM&A
Investments96 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about RiverVest
What does RiverVest do?
RiverVest Venture Partners is a life science venture capital firm that raises dedicated funds (Funds I through V, the Archer Seed Fund, and the 3x5 Special Opportunity Fund) from institutional investors and invests the committed capital as equity into early-stage biopharmaceutical and medical device companies. The firm earns revenue through management fees on committed capital and carried interest on profitable exits, and provides portfolio companies with board representation, strategic guidance, and access to its scientific and clinical network.
Is RiverVest a public or private company?
RiverVest is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was RiverVest founded?
RiverVest was founded in 2000. It employs 11 to 50 people.
Where is RiverVest based?
RiverVest is headquartered in St Louis, United States, in the North America region.
How does RiverVest make money?
Two revenue lines are on record. Management Fees are the primary driver. The others are carried Interest.
Who are RiverVest's main competitors?
New Enterprise Associates (NEA) is listed as a broad incumbent. Direct peers are OrbiMed, Atlas Venture, ARCH Venture Partners, Longitude Capital, Frazier Life Sciences, Hatteras Venture Partners, Versant Ventures, 5AM Ventures and Sanderling Ventures.
Does RiverVest have an API?
No public API is recorded for RiverVest.
What industry is RiverVest in?
RiverVest's product category is Life Science Venture Capital. Its primary akta.pro industry code is FSANAAAD, Sector-Focused Venture Capital (Vertical Specialists), with a secondary code of FSANAAAB, Early-Stage Venture Capital (Series A/B). Its NAICS code is 525 and its SIC code is 6282.